Related Experiment Videos
Monoclonal antibody strategies to block angiogenesis
1ImClone Systems, 180 Varick Street, 10014, New York, NY, USA
Abstract:
Antibodies represent a unique class of therapeutics because of their high specificity towards a defined target antigen. Recent clinical success with antibody-based cancer therapeutics has led to an increase in the clinical development of these agents. Antibody therapeutics offer a promising approach for inhibiting new blood vessel formation (angiogenesis), which is associated with a variety of diseases, including cancer. In this review we will focus on angiogenesis-related mechanisms targeted by antibody-based therapeutics, with an emphasis on those studies where pre-clinical in vivo data is available.
Insights
Antibody therapeutics show promise for treating diseases like cancer by targeting new blood vessel formation (angiogenesis). This review focuses on antibody-based strategies and pre-clinical data for inhibiting angiogenesis.
Area of Science:
- Immunology and Oncology
- Therapeutic Antibody Development
Background:
- Antibodies are highly specific therapeutics with increasing clinical success in cancer treatment.
- Angiogenesis, or new blood vessel formation, is a key process in diseases like cancer.
- Antibody therapeutics present a promising strategy for targeting angiogenesis.
Purpose of the Study:
- To review antibody-based therapeutics targeting angiogenesis.
- To focus on angiogenesis-related mechanisms.
- To emphasize pre-clinical in vivo data.
Main Methods:
- Literature review of antibody-based angiogenesis inhibitors.
- Analysis of pre-clinical in vivo studies.
- Focus on mechanisms of action.
Main Results:
- Antibodies can effectively target key pathways in angiogenesis.
- Pre-clinical data supports the efficacy of various antibody-based strategies.
- Specific examples of antibody targets in angiogenesis are discussed.
Conclusions:
- Antibody therapeutics are a viable and developing approach for anti-angiogenesis therapy.
- Further research and clinical development are warranted.
- Pre-clinical in vivo data is crucial for validating these therapeutic strategies.